Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Joseph Bisaha, David Jackson

Premium

Arno Therapeutics has appointed Joseph Bisaha as its new VP of clinical operations and project management and David Jackson as its VP of diagnostics. In their new positions, both Bisaha and Jackson will support the development of the personalized cancer drug onapristone, Arno's lead product.

Before joining Arno, Bisaha was a clinical research consultant with Kaizen Clinical Services, where he handled Arno's clinical Operations and project management activities. During his 17-year career, he has held various management roles, including associate VP of project management at ImClone Systems and senior director of clinical research and drug development at Ono Pharma.

Jackson comes to Arno from molecular testing firm PrimeraDx where he was VP of business development. Jackson also was senior director of companion diagnostic partnerships at Qiagen Manchester and consulted drug and diagnostics developers on the development and commercialization of personalized medicines and companion tests.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.